Table 3.
AMA1 vaccine group | Control group | |||
---|---|---|---|---|
No primary outcome episodes before day 90 (n = 66) | No primary outcome episodes before day 90 (n = 22) | |||
Predictor variable | Hazard ratioc | P | Hazard ratio | P |
log10 (IgG1 day 90) | 1.17 [0.47, 2.93] | 0.74 | 1.14 [0.65, 2.00] | 0.66 |
log10 (IgG2 day 90) | 0.92 [0.5, 1.70] | 0.79 | 1.27 [0.43, 3.72] | 0.66 |
log10 (IgG3 day 90) | 1.89 [0.99, 3.61] | 0.053 | 0.93 [0.35, 2.43] | 0.87 |
log10 (IgG4 day 90) | 1.06 [0.69, 1.63] | 0.79 | 8.45 [0.61, 116.86] | 0.11 |
log10 (cytophilic ratiod day 90) | 0.83 [0.40, 1.70] | 0.61 | 1.05 [0.44, 2.53] | 0.91 |
aGap time models with common regression coefficients using Firth’s penalized likelihood
bClinical malaria episode defined using the primary outcome definition, i.e., an episode of malaria with axillary temperature of ≥ 37.5 °C and asexual P. falciparum density of ≥ 2500 parasites/mm3 of blood
cHazard ratio and 95% confidence intervals for risk of multiple clinical malaria episodes after day 90
dCytophilic ratio is the sum of IgG1 and IgG2 titers divided by the sum of the IgG3 and IgG4 titers